Microport Crm France Sas

Commerce de gros de produits pharmaceutiques

4 avenue Reaumur 92140 Clamart

Indice de confiance

Laissez un avis

Chiffre d'affaires 2018

95,5 M€

Président

Paul

V.

Vodden

Effectif 2018

96

Ancienneté

15 ans

Indicateurs

À propos

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
At LivaNova we strive to help where it really counts, where it truly matters the most. Where every single effort, of each one of us, is transformational and ex…pected to leave a lasting mark. That is why at LivaNova we make each innovation count: global, accessible, relevant and breakthrough. Transforming medical innovation into meaningful solutions, into a sustainable healthcare system and ultimately into healthier and – importantly - better lives. Afficher la suiteSource : Facebook

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 4,000 employees. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.Source : Youtube

Vente de dispositifs médicaux en France.Source : BODACC

Le SIREN de la société Microport Crm France Sas est : 477828412. Celle ci disposait d'un capital de 82 200 000 euros au cours de l'année 2011. Elle est domiciliée dans la ville de Clamart. La structure dénommée Microport Crm France Sas exerce dans le commerce en gros de produits pharmaceutiques. Le chiffre reflétant l'indice de confiance qui a été établi pour cette entreprise est de 95 sur 100. Paul Vodden est le Président de cette dernière. Le numéro de TVA correspondant à l'activité de Microport Crm France Sas est : FR42477828412. Son immatriculation s'est effectuée pendant l'année 2004. Il y avait 96 salariés qui travaillaient pour le compte de celle-ci pendant l'année 2018. Cette structure est présente sur le web : elle dispose d'une page Facebook. Le nom de cette dernière est livanovaplc et son nombre de likes est de 1790.

Fiche d'identité

  1. Type Société par actions simplifiée à associé unique (SASU)
  2. Date de création 07/07/2004
  3. Effectif 96 (2018)
  4. Capital social 82 200 000€ (2011)
  5. Chiffre d'affaires 95,5 M€ (2018)
  6. TVA intercommunautaire FR42477828412
  7. Numéro de SIREN 477828412
  8. Code NAF Commerce de gros de produits pharmaceutiques (4646Z)
  9. Statut SIRENE Active
  10. Statut RCS Active

Expertises

  1. Conditionnement

Contacts

Capture d'écran du site de Microport Crm France Sas

Réseaux sociaux

Téléphone

Inscrivez-vous gratuitement

Il s’agit de votre entreprise ?

Mettez en valeur votre activité en complétant les informations de cette page et invitez vos partenaires à vous évaluer pour construire votre e-réputation.

Revendiquez votre page gratuitement !

Avis Microport Crm France Sas (0)

Que pensez-vous de Microport Crm France Sas ?

Actuellement aucun avis publié, soyez le premier !

Laisser un avis

Dirigeants Microport Crm France Sas (5)

Âge moyen des dirigeants

53 ANS

Durée moyenne de mandat

3 ANs 2 MOIS

Parité

0%100%
  • Paul Vodden

    Président

    2016 - Présent

    En poste

    @ PRO

  • Kpmg SA

    Commissaire aux comptes titulaire

    2018 - Présent

    En poste

    @ PRO

  • Vous voulez voir plus d'infos dirigeants ?

    Créez un compte pour accéder à l'ensemble des données sur cette entreprise.

    Inscrivez-vous gratuitement

Chiffre d'affaires, bilans Microport Crm France Sas (3)

Durée de l'exercice comptable : 12 mois

Comptes saisis avec des incohérences selon l'INPI

Chiffre d'affaires

95,5 M€

-19,8 %

Résultat net

-301,2 k€

-108,9 %

Capacité d'autofinancement

-1,9 M€

-189,8 %

Chiffres d'affaires

Vous voulez le détail des comptes ?

Créez un compte et téléchargez gratuitement le bilan et le compte de résultat des comptes sociaux déposés en 2018 par Microport Crm France Sas

Télécharger les comptes

Chiffres clés

Chiffre d'affaires

95,5 M€

-19,8 %

Les ventes sont en fort recul par rapport à l'exercice précédent.

Résultat net

-301,2 k€

-108,9 %

Capacité d'autofinancement

-1,9 M€

-189,8 %

L'activité de l'entreprise ne rapporte pas suffisamment de recettes pour couvrir les dépenses d'exploitation.

Taille du bilan

102,2 M€

-1,5 %

Fonds propres

83,6 M€

-0,4 %

Cette entreprise présente des fonds propres nettement supérieurs à la plupart des entreprises à chiffre d'affaires égal.

Trésorerie nette

1,9 M€

103 978,5 %

L'entreprise consomme quasi-intégralement (97,8%) son fonds de roulement, de sorte qu'elle garde peu de marge de manœuvre en matière de trésorerie.

Ratios financiers

Rendement des fonds propres

0,1 %

-97,9 %

Cette entreprise réalise un bénéfice avant éléments exceptionnels et impôts sur les sociétés et a des fonds propres positifs ; ce chiffre peut donc être interprété comme un rendement du capital investi.

Equilibre financier

1 426,8 %

Autonomie financière

81,8 %

1,2 %

Les fonds propres dépassent la moitié du passif de l'entreprise, ce qui lui apporte de la robustesse.

Liquidité générale

6,1

8,8 %

Délai moyen clients

50 jours

À la date d'arrêté des comptes, les créances clients représentent moins de 2 mois de chiffre d'affaires ; cela procède probablement de délais de paiement conformes à la loi.

Délai moyen fournisseurs

33 jours

22,2 %

À la date d'arrêté des comptes, les dettes envers les fournisseurs représentent moins de 2 mois d'achats, ce qui est conforme à la loi si cela peut s’interpréter comme son délai de paiement moyen.

Liens capitalistiques

PRO

Accédez aux liens capitalistiques

Découvrez la structure du groupe auquel appartient cette entreprise : tête de groupe, actionnaire majoritaire et filiales.

En savoir plus

Annonces légales (10)

  • Dépôt des comptes

    26 juil. 2012

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2011, auprès du tribunal de commerce ou d'instance.

  • Modification

    31 janv. 2012

    SORIN GROUP FRANCE a renouvelé tout ou partie de ses dirigeants ou de son administration. Celle-ci devient :
    Commissaire aux comptes suppléant : AUDITEX en fonction le 31 Août 2010 Commissaire aux comptes titulaire : ERNST & YOUNG et Autres en fonction le 31 Août 2010 Président : VODDEN Paul en fonction le 23 Janvier 2012.

  • Dépôt des comptes

    26 juil. 2011

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2010, auprès du tribunal de commerce ou d'instance.

  • Modification

    7 avr. 2011

    Le capital social de SORIN GROUP FRANCE est porté à 82 200 000 €.

  • Dépôt des comptes

    23 sept. 2010

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2009, auprès du tribunal de commerce ou d'instance.

  • Modification

    9 sept. 2010

    SORIN GROUP FRANCE a renouvelé tout ou partie de ses dirigeants ou de son administration. Celle-ci devient :
    Président : TAIT Grant modification le 31 Juillet 2009 Commissaire aux comptes suppléant : AUDITEX en fonction le 31 Août 2010 Commissaire aux comptes titulaire : ERNST & YOUNG et Autres en fonction le 31 Août 2010.

  • Modification

    24 sept. 2009

    SORIN GROUP FRANCE a transféré son siège social (sans changer de ressort de tribunal) à l'adresse 4 avenue Réaumur - 92140 Clamart.

  • Dépôt des comptes

    24 sept. 2009

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2008, auprès du tribunal de commerce ou d'instance.

  • Modification

    30 juil. 2009

    SORIN GROUP FRANCE a renouvelé tout ou partie de ses dirigeants ou de son administration. Celle-ci devient :
    Commissaire aux comptes titulaire : ERNST & YOUNG AUDIT Commissaire aux comptes suppléant : ANTOLA Any Président : TRAIT Grant en fonction le 22 Juillet 2009.

  • Dépôt des comptes

    26 août 2008

    L'entreprise a enregistré ses comptes annuels et rapports, clos au 31/12/2007, auprès du tribunal de commerce ou d'instance.

  • Vous voulez voir toutes les annonces légales ?

    Créez un compte pour accéder à l'ensemble des données sur cette entreprise.

    Inscrivez-vous gratuitement

Adresses Microport Crm France Sas (7)

  • Siret : 47782841200072 (siège social)

    Actif

    4 avenue Reaumur 92140 Clamart

    Commerce de gros de produits pharmaceutiques (4646Z)

    1 sept. 2009

    100 à 199

    Siret : 47782841200023

    Fermé

    217 la Boursidiere (Batiment Jura) 92350 Le Plessis-Robinson

    Commerce de gros de produits pharmaceutiques (4646Z)

    1 sept. 2004

    1 janv. 2012

  • Siret : 47782841200031

    Fermé

    316 route de Saint Simon 31100 Toulouse

    Commerce de gros de produits pharmaceutiques (4646Z)

    1 sept. 2004

    1 janv. 2012

    Siret : 47782841200049

    Fermé

    217 cours Lafayette 69006 Lyon

    Commerce de gros de produits pharmaceutiques (4646Z)

    31 août 2004

    1 janv. 2012

  • Siret : 47782841200056

    Fermé

    2 impasse Michel Labrousse (la Maison des Lois) BP 1137 31100 Toulouse

    Commerce de gros de produits pharmaceutiques (4646Z)

    31 août 2004

    1 janv. 2012

    Siret : 47782841200064

    Fermé

    54 rue d'Arcueil (54 au 56Parc d'Affaires Si) 94150 Rungis

    Recherche-développement en sciences physiques et naturelles (7219Z)

    31 août 2004

    1 janv. 2012

  • Siret : 47782841200015

    Fermé

    la Boursidiere (Centre d'Affaires) 92350 Le Plessis-Robinson

    7 juil. 2004

    25 déc. 2004

Trafic du site web

Accédez aux statistiques du site web

Évaluez l'empreinte digitale de cette entreprise et son évolution grâce aux statistiques sur son trafic mensuel, ses sources du trafic, le temps passé par les internautes, etc.

Inscrivez-vous GRATUITEMENT

Réseaux sociaux Microport Crm France Sas (2)

Vidéos Microport Crm France Sas (50)

  • IMPLANTATION: Memo 3D Rechord - Ready To Repair | LIVANOVA

    14 mars 2017

    This is Memo 3D Rechord. This 3D animation shows how it sould be implanted. Memo 3D Rechord has an innovative guiding system for standardized procedures. It features a unique super-elastic alloy core for truly physiological annular dynamics. It has great performance thanks to its exclusive Carbofilm coating, for physiologic endothelialization. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • INSPIRE: Celebrating 1 Million Patients Treated, 1 Million More Smiling Faces | LIVANOVA [IM-01478A]

    24 avr. 2018

    We celebrate 1 million patients treated with Inspire, and 1 million more smilling faces. Inspire is a family of adult oxygenators designed by LivaNova from years of research and laboratory experience, input from clinical experts from around the world and the application of advanced manufacturing technologies that adhere to the highest quality standards. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01478A]

  • The Role of Washed Autotransfusion in Patient Blood Management | LIVANOVA [IM-01581A]

    27 avr. 2018

    For decades, physicians have understood the power of blood transfusions in correcting physiologic abnormalities associated with anemia and their life saving potential in actively bleeding patients in cardiac and non cardiac surgery. In order to reduce allogeneic transfusions and associated risks, hospitals are developping patient blood management strategies. They minimize blood loss and anemia. One particularly notable therapy available to minimize intraoperative blood loss is washed auto transfusion. It consists of the collection, concentration, washing and reinfusion of the patient's own blood. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01581A]

  • CARBOMEDICS AORTIC FAMILY: Complete Set of Mechanical Heart Valve Solutions | LIVANOVA

    10 janv. 2017

    Carbomedics aortic family, tailored reliability for patients and surgeons. Adult and Pediatric bileaflet mechanical heart valves, a leader in biocompatible materials with a robust design for no structural failure. Carbomedics valves are designed for a smooth implant experience - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • CLINICAL EXPERIENCE: Prof. B. Meuris - my 10 years of experience with Perceval valve

    25 juil. 2017

    Prof Bart Meuris shares his experience and discusses the disruptive technology brought by sutureless valves like Perceval. He explains what it means for Perceval to have reached 10 years of clinical experience. He talks about Perceval's key features and highlights the advantages of the Perceval valve versus the conventional valves. He later describes how this new technology has held its promises. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • CORPORATE VIDEO: We are LivaNova. We provide health innovation that matters. | LIVANOVA

    30 avr. 2018

    We are LivaNova. We develop advanced technologies and breakthrough treatments to provide meaningful solutions around the world. We provide health innovation that matters. Day by day. Life by life. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • INSIDE OUR FACILITY IN MUNICH: a Vocation for Innovation | LIVANOVA [IM-00946A]

    1 août 2017

    Our vision is to make a difference in Cardiac Surgery Solutions. At our Munich facility, we have a vocation for innovation. We continue to invest in breakthrough technologies to develop innovative solutions for the healthcare system. A global outlook towards innovative ideas to enhance patient care. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 00946A]

  • INTERVIEW: Dr Thomas Dreizler - S5 Heart-Lung Machine: 40 Years of Leadership | LIVANOVA

    29 nov. 2017

    Dr Thomas Dreizler answers a few questions about LivaNova's S5 heart-lung machine. First of all, what are his experctations for a HLM? What features on the S5 are important to him? How he uses the S5 to achieve the highest safety? Which features or functions he uses to achieve optimum patient support during ECC? And also, is the S5 flexible enough to face every challenge of cardiac surgery? LivaNova’s fifth-generation modular heart-lung machine has set new standards for functionality, flexibility and quality. Designed for many years of demanding performance, the advanced design allows for: - Better integration with the perfusion circuit - More configuration options to accommodate a greater assortment of procedures (including pediatric) - Quick and easy exchange of individual components in the most challenging environments - Unprecedented safety features As upgrades can be implemented at any time, the S5 system will remain state-of-the-art for many years to come. Addressing Individual Needs From a small, compact HLM equipped with three roller pumps to a full-featured system with seven roller pumps and the full range of control and monitoring functions, the S5 can be configured to individual requirements and budget considerations. - Visit us at www.livanova.com For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • The S5 HLM, by LivaNova - The Most Successful Heart-Lung Machine Ever | LIVANOVA [IM 02250A]

    12 févr. 2019

    For 10 years, the S5 system has been setting the bar high for heart-lung machine quality, performance and modular flexibility. It is now the perfusionists' solution of choice, bringing functionality, reliability and overall quality. It is designed and built in Munich, Germany for many years of demanding performance. Patients get state-of-the-art equipment accommodating to a greater assortment of procedures (including paediatrics). - Designed for many years of demanding performance, the advanced design allows for: - Better integration with the perfusion circuit - More configuration options to accommodate a greater assortment of procedures (including pediatric) - Quick and easy exchange of individual components in the most challenging environments - Unprecedented safety features As upgrades can be implemented at any time, the S5 system will remain state-of-the-art for many years to come. - Visit us at www.livanova.com

  • SUTURELESS VALVE: a New Type of Aortic Valve Replacement, Dr Kevin Teoh | LIVANOVA

    23 janv. 2017

    Dr Kevin Teoh explains what is a sutureless valve and how this is a new type of aortic valve replacement (AVR). Until then, AVR had been a heavily invasive procedure in North America. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • Join the New Perceval App | LIVANOVA

    22 févr. 2017

    Download the new Perceval app, now even more complete in order to get a 360° experience: - Heartbeat activation - Exploded view - Product information - Related contents to get mastery of the valve - Expert resources to discover all about Perceval. - Training especially designed for nurses and surgeons. - New Augmented Reality experience - and much more ... - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • IMPLANTATION: Carbomedics Top Hat with Dr D. Bouchard | LIVANOVA

    10 janv. 2017

    Dr D. Bouchard's implant video. Carbomedics aortic family, tailored reliability for patients and surgeons. Adult and Pediatric bileaflet mechanical heart valves, a leader in biocompatible materials with a robust design for no structural failure. Carbomedics valves are designed for a smooth implant experience - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • CLINICAL EXPERIENCE: My 10 Years of Experience with the Perceval Valve, Prof A. Haverich | LIVANOVA

    7 juin 2017

    Prof Axel Haverich shares his clinical experience and discusses the disruptive technology brought by sutureless valves like Perceval and what it meant 10 years ago. Back then, sutureless was somewhat futuristic. Still, considering the pool of patients, this technology was seen as very favourable. He then talks about Perceval, by LivaNova directly, what is has represented in his practice. Lastly, Prof Axel Haverich goes back on his extensive experience with Perceval and agrees that the technology held its promises. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • Mechanical Heart Valves: Benefits of a Lower INR Management | LIVANOVA [IM-01163A]

    27 mars 2018

    Mechanical Heart Valves: Benefits of a Lower INR Management Heart valve can be replaced by either mechanical or tissue valves. Many factors go into this decision, including age and life expectancy, other considerations and patient lifestyle preferences. Both types of valve replacements have pros and cons. Tissue valves are subjects to structural valve deterioration over time. Mechanical valves require the use of anti-coagulants for the rest of the patient's life to reduce the chance of clot formation. The ability of the blood to clot is measured by the International Normalized Ratio (INR). Here are the benefits of a lower INR management. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01163A]

  • Xtra® Autotransfusion System: Quick start

    26 mars 2019

    These Quick Operating Instructions represent only an overview of the operating procedures. For a complete setup and use of the machine for intraoperative blood recovery, please refer to the XTRA Operator’s Manual. - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. IM-02381 B

  • The Role of Washed Autotransfusion in Patient Blood Management | LIVANOVA [IM 01580A]

    27 avr. 2018

    For decades, physicians have understood the power of blood transfusions in correcting physiologic abnormalities associated with anemia and their life saving potential in actively bleeding patients in cardiac and non cardiac surgery. In order to reduce allogeneic transfusions and associated risks, hospitals are developping patient blood management strategies. They minimize blood loss and anemia. One particularly notable therapy available to minimize intraoperative blood loss is washed auto transfusion. It consists of the collection, concentration, washing and reinfusion of the patient's own blood. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01580A]

  • OPTIFLOW ARTERIAL CANNULAE: Less Jet, More Natural Dispersion | LIVANOVA [IM-01090A]

    26 sept. 2017

    Optiflow arterial cannulae: Less Jet, More Natural Dispersion Neurologic complications during on-pump cardiovascular surgery are often induced by mobilization of atherosclerotic plaques linked to enhanced wall shear stress of the arterial cannula jet flow. Optiflow arterial cannula features a unique basket tip with large openings that allow a more physiological flow. Optiflow has shown to reduce the pressure on the inlet jet system on the aorta, thus mitigating arterial embolization of atherosclerotic plaques. - Visit us at www.livanova.com and www.cannulae.livanova.com For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01090A]

  • INTERVIEW: Frank Merkle - S5 Heart-Lung Machine: 40 Years of Leadership | LIVANOVA [IM-01183A]

    24 mai 2018

    This in an interview of Frank Merkle, from the Academy of Perfusion at the German Heart Centre in Berlin, Germany. He answers questions about the importance of incident-management in perfusion, about the advantages of simulation training for perfusionists. He then explains how the correct handling of the heart-lung machine and goal directed perfusion can improve the patient outcome and how to avoid critical situations during perfusion. Finally, he discusses the goal and benefit of perfusion training in Berlin, in co-operation with LivaNova. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01183A]

  • CLINICAL EXPERIENCE: 10 Years of Experience with Perceval - Prof Malakh Lal Shrestha | LIVANOVA

    22 sept. 2017

    Prof Malakh Lal Shrestha shares his experience and discusses the disruptive technology brought by sutureless valves like Perceval. He explains what it means for Perceval to have reached 10 years of clinical experience. He remembers what it felt like, during the first implant. He talks about Perceval's key features and highlights the advantages of the Perceval valve versus the conventional valves. He later describes how this new technology has held its promises. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • INSPIRE: 1 Million Patients Treated 1 Million More Smiling Faces – Ruth Gold | LIVANOVA [IM 01514A]

    25 mai 2018

    We celebrate 1 million patients treated with Inspire, and 1 million more smilling faces. This video features R. Gold. Inspire is a family of adult oxygenators designed by LivaNova from years of research and laboratory experience, input from clinical experts from around the world and the application of advanced manufacturing technologies that adhere to the highest quality standards. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01514A]

  • Memo 4D | Reshaping Mitral Repair - Resect vs. Respect

    6 mars 2019

    IM 1353 A 9364

  • Xtra® Autotransfusion System: Overview

    26 mars 2019

    The adoption of a washed autotransfusion system should be considered as a key strategy to guarantee patient safety, and as a central resource to your Patient Blood Management programme. - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. IM-01581 A IM-02381 B

  • Xtra® Autotransfusion System: Operating the System

    26 mars 2019

    Xtra, LivaNova's extraordinarily innovative, intuitive, and powerful autotransfusion system is ready to meet your patient blood management needs. - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. IM-01581 A IM-02381 B

  • That's Why - Health Innovation That Matters - Campaign | LIVANOVA

    9 avr. 2018

    Perceval: 10 years of experience. More years to love. Carbomedics: 30 years of clinical use. A full life to live. Heart-Lung Machine: 40 years of leadership. More years for new goals. Connect: Over 20 years of experience. More years for new horizons. Xtra: More than 1 million patients treated. A million more moments to live. Cannulae: Many years of commitment. Even more years of innovation. LivaNova, That's Why campaign. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • CLINICAL EXPERIENCE: 10 Years of Experience with Perceval - Dr Mattia Glauber | LIVANOVA

    13 nov. 2017

    Dr Mattia Glauber shares his experience and discusses the disruptive technology brought by sutureless valves like Perceval. He explains what it means for Perceval to have reached 10 years of clinical experience. He remembers what it felt like, during the first implant. He talks about Perceval's key features and highlights the advantages of the Perceval valve versus the conventional valves. He later describes how this new technology has held its promises. Will sutureless technology play a large role in the next 10 years? - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • Bicarbon Aortic Valves Approval With Lower INR: Clinical Foundation | LIVANOVA [IM-01343A]

    13 juin 2018

    The clinical foundation showing the benefits of bicarbon with a spontaneous randomized study. Low INR and not a single thromboembolic event, making it a lifelong solution. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01343A]

  • SYMPOSIUM (Lunch): 10 Years of Clinical Use, Prof Bart Meuris | LIVANOVA

    25 oct. 2017

    In this lecture at EACTS (symposium), Prof Bart Meuris talks about the 10 years of clinical use of LivaNova's Perceval valve. This keynote addressed the 10 years of existence of the sutureless valve technology, going back to the 3 consecutive clinical trials, and Prof Bart Meuris states that LivaNova set an example in launching a new technology. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • HEART STORIES: Maria, 10 Years After the Aortic Valve Replacement w/ Perceval | LIVANOVA [IM-00986]

    9 mai 2017

    What have the last 10 years been for Maria, since she received an aortic valve replacement? According to her, her life was full of action, joy and unique moments. Once she realised she was no longer able to do the things she had always done, the things she enjoyed, the family realised that she needed a new heart valve, at age 84. This was why she was always tired and short of breath. Eventually, she recovered completely. This is her story, her Heart Story. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 00986]

  • What's Behind (and Beyond...) Bicarbon Aortic Valves' Lower INR Indication | LIVANOVA [IM 01198A]

    3 mai 2018

    What is behind (and beyond...) Bicarbon Aortic Valves' lower INR indication? In order to have the greatest level of safety and best quality of life, you want the mechanical valve to have the higghest possible hemodynamic performance with the lowest thrombogenecity, accompanied by a track record of long-term clinical data. When it comes to clinical performance, design details make the difference. Bicarbon mechanical valve by LivaNova features the most innovative product design available on the market. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01198A]

  • Who We Are | LIVANOVA

    26 nov. 2018

    LivaNova is a global medical technology company built on decades of experience and a relentless commitment to improve the lives of patients around the world. As a worldwide leader in cardiovascular and neuromodulation solutions, we are dedicated to helping create meaningful products and therapies that transform lives each and every day. It’s health innovation that truly matters. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • Memo 4D annuloplasty ring - Anterior Leaflet Implantation Animation

    5 mars 2019

    - Visit us at www.livanova.com For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 02264 A]

  • INSPIRE: Interviews - Best of Perfusionists, Jonathan Sheppard & Mauro Bosi | LIVANOVA [IM 01515A]

    20 juin 2018

    Lead clinical perfusionists Jonathan Sheppard (UK) and Mauro Bosi (Italy) explain how good patient perfusion is paramount to success in cardiac surgery. Both professionals have confidence in the broad family of Inspire oxygenators manufactured by LivaNova, which has a long standing history of oxygenator design. These reliable systems enable cardiac teams around the world to safely perform cardiac procedures. Inspire is a family of adult oxygenators designed by LivaNova from years of research and laboratory experience, input from clinical experts from around the world and the application of advanced manufacturing technologies that adhere to the highest quality standards. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01518A]

  • Xtra® Autotransfusion System: System and Disposable Installation

    26 mars 2019

    Customers appreciate the XTRA autotransfusion system for the unique combination of equipment features, including: • Multiple emergency protocols • Quality management controls (with a Built-in HCT Sensor and Wash Quality Indicators) • Data management via USB, printer, and standard RS232 computer port • Preoperative sequestration capability (automatic or manual) • Custom protocol creation - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. IM-02381 B

  • CLINICAL EXPERIENCE: 10 Years of Experience with Perceval - Laura Ghione | LIVANOVA

    25 janv. 2018

    Laura Ghione is Heart Valve R&D Director at LivaNova. She shares special moments from her 20 years of working experience, with a particular fondness for the moment Perceval was approved for the European market. She explains how she came up with the idea of a sutureless valve, to keep the valve in place in order to prevent it from leaking. She also discusses the importance of regular contact with surgeons and patients. She then talks about what it means for her team to develop a technology that will be at the heart of people's lives. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • CLINICAL EXPERIENCE: 10 Years of Experience with Perceval - Brian Duncan | LIVANOVA

    8 févr. 2018

    Brian Duncan is Vice President of Medical Affairs at LivaNova. He shares his insights about what it meant to implant a sutureless valve 10 years ago. Furthermore, he explains the importance of the human factor when investing in new technologies. And with 10 years of clinical experience, what does Perceval mean for the surgeons and their patients. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • MHV In Today's Clinical Practice: Advantages & Challenges, Dr D. Bouchard | LIVANOVA

    10 janv. 2017

    Dr D. Bouchard talks about the advantages and challenges of Mechanical Heart Valve (MHV) in today's clinical practice. Which patient profile is best suited for mechanical prosthesis? What is the assessment about valve in valve procedures? What features should a mechanical valve have in aortic position, and in mitral position? - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • BICARBON VALVES: Voices of Experience with Prof U. Bortolotti & Dr R. Coppola | LIVANOVA

    10 janv. 2017

    Prof U. Bortolotti and Dr R. Coppola talk about the Bicarbon valves, by LivaNova. How long they have been using it in their practice, why they chose it, which benefits it can bring to their patients etc. They also discuss clinical results and patients for which it is advised. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • CLINICAL EXPERIENCE: 10 Years of Experience with Perceval - Pr. Claudio Muneretto | LIVANOVA

    27 mars 2018

    Prof Claudio Muneretto shares his experience and discusses the disruptive technology brought by sutureless valves like Perceval. He explains what it means for Perceval to have reached 10 years of clinical experience. In his opinion, this is a very important landmark. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • HEART STORIES: Mariano, My Life Restored Thanks to Perceval | LIVANOVA [IM-01450A]

    17 avr. 2018

    Mariano is 56 years old. He was implanted with a Perceval valve at the age of 54. He was operated through a small incision. He has then gone back to living a full and active life. He is a craftsman from Montecatini. He had heart problems. Now he doesn't feel tired most of the time, which is wonderful considering he's passionate about his job. Dr Mattia Glauber confirms that Perceval can be implanted in many critical clinical situations, including minimally invasive cardiac surgery. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01450A]

  • INSPIRE: 1 Million Patients Treated 1 Million More Smiling Faces - Insiders | LIVANOVA [IM-01518A]

    17 sept. 2018

    We celebrate 1 million patients treated with Inspire, and 1 million more smilling faces. This video features our insiders, Adriano Mazzoli, Clara Pandolfini, Mark Orangio, Claudio Silvestri, Patti Cummings, Sabrina Carletti, Christiano Guglielmi and Carlijn Thissen. Inspire is a family of adult oxygenators designed by LivaNova from years of research and laboratory experience, input from clinical experts from around the world and the application of advanced manufacturing technologies that adhere to the highest quality standards. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01518A]

  • CARBOMEDICS VALVES: Voices of Experience with Dr D. Bouchard & Dr P. Garceau | LIVANOVA

    10 janv. 2017

    Dr D. Bouchard and Dr P. Garceau answer questions about the use of Carbomedics valves in their clinical practice. Why they chose Carbomedics, what benefits it brings to their patients? - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • Xtra® Autotransfusion System: Cleaning and Maintenance

    26 mars 2019

    Apart from the hygienic aspect, it is essential for the operational safety and reliability of the XTRA autotransfusion system that it be kept clean. Perform the following cleaning routine every time. Before cleaning the XTRA, disconnect it from the mains power supply and ensure that the system is switched off. The complete instructions for routine maintenance can be found in the XTRA operator’s manual. - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. IM-02381 B

  • SYMPOSIUM (Lunch): Annuloplasty Role for Complex Mitral Repair, Taweesak Chotivatanapong | LIVANOVA

    20 nov. 2017

    In this lecture, Dr Taweesak Chotivatanapong from the Central Chest Institute of Thailand, Department of Cardiothoracic Surgery talks about "Annuloplasty Role for Complex Mitral Repair". - Visit us at www.livanova.com For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • INTERVIEW: My approach to AVR with Perceval and MICS cannulae, Dr Paulo Neves | LIVANOVA [IM 02072A]

    14 févr. 2019

    Dr. Paulo Neves explains why, in his opinion, the LivaNova EASYFLOW cannula is the "easiest cannula available" to perform aortic cannulation in minimally invasive procedures and why he uses the LivaNova RAP femoral venous cannula for all types of MICS procedures - from aortic, to mitral and tricuspid operations. He also discusses the main benefits of using LivaNova MICS Cannulae in combination with the PERCEVAL valve. This product may not be for sale in your country or your area. For further information on product availability, please contact your local representative. For indications, contraindications, precautions and warnings for each device, please refer to the Instructions For Use. - Visit us at www.livanova.com - INDICATIONS: EUROPE: The Perceval prosthesis is indicated for the replacement of diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated for use in adult patients who are diagnosed to have aortic valve stenosis or steno-insufficiency. USA: The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. CANADA: The Perceval S bioprosthesis is intended for use in patients aged ≥ 65 years when the aortic valve pathology is in an advanced stage to require the replacement of the native or malfunctioning previously implanted prosthesis. AUSTRALIA: Perceval S prosthesis is indicated for the replacement of a diseased native or a malfunctioning prosthetic aortic valve via open heart surgery. The prosthesis is indicated in patients who meet the following criteria: 1) subjects of age ≥ 65 years 2) subjects with aortic valve stenosis or steno-insufficiency. TOP POTENTIAL SIDE EFFECTS: The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the PERCEVAL prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. MRI conditional For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 02072A]

  • INSPIRE: 1 Million Patients Treated 1 Million More Smiling Faces – Uday Trivedi | LIVANOVA

    13 juil. 2018

    We celebrate 1 million patients treated with Inspire, and 1 million more smilling faces. This video features U. Trivedi. Inspire is family of adult oxygenators designed by LivaNova from years of research and laboratory experience, input from clinical experts from around the world and the application of advanced manufacturing technologies that adhere to the highest quality standards. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01518A]

  • INSPIRE: 1 Million Patients Treated 1 Million More Smiling Faces A. Edvinsson | LIVANOVA [IM-01519A]

    9 oct. 2018

    We celebrate 1 million patients treated with Inspire, and 1 million more smilling faces. This video features A. Edvinsson. Inspire is a family of adult oxygenators designed by LivaNova from years of research and laboratory experience, input from clinical experts from around the world and the application of advanced manufacturing technologies that adhere to the highest quality standards. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01519A]

  • INSPIRE: 1 Million Patients Treated 1 Million More Smiling Faces - B. Duncan | LIVANOVA [IM-01518A]

    8 août 2018

    We celebrate 1 million patients treated with Inspire, and 1 million more smilling faces. This video features B. Duncan. Inspire is a family of adult oxygenators designed by LivaNova from years of research and laboratory experience, input from clinical experts from around the world and the application of advanced manufacturing technologies that adhere to the highest quality standards. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01518A]

  • EASYFLOW: direct arterial cannulation in MICS | LIVANOVA [IM 01823A]

    12 déc. 2018

    Minimally Invasive Aortic Cannulation performed by Dr. Tedoriya with the LivaNova EASYFLOW cannula, to show how the cannula's stiffness facilitates remote insertion thanks to its unique design. This product may not be for sale in your country or your area. For further information on product availability, please contact your local representative. For indications, contraindications, precautions and warnings for each device, please refer to the Instructions For Use. - Visit us at www.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM 01823A]

  • SYMPOSIUM (Lunch): AVR Patient Selection in Changing Landscape, Dr Claudio Muneretto | LIVANOVA

    25 oct. 2017

    In this lecture at EACTS (symposium), Prof Claudio Muneretto talks about Aortic Valve Replacement patient selection in a changing landscape. This keynote touches on many different important points, including Transcatheter aortic valve implantation. He then compares Sutureless and TAVR. - Visit us at www.livanova.com For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.

  • LivaNova MICS cannulae: Expanding performance standards

    30 mai 2019

    High performance cannulae for direct and femoral cannulation in Minimally Invasive Cardiac Surgery (MICS). LivaNova’s complete range of MICS dedicated products allow easily and reproducible procedures. Discover our full portfolio on www.livanova.com - Visit us at cannulae.livanova.com - For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling. [IM-02051A]

Entreprises - Hauts-de-Seine (92) - Clamart (92140)

Allez plus loin avec B-Reputation

Découvrez comment nos données peuvent répondre à vos besoins.

Veille stratégique

  • Fiches entreprises complètes
  • Alertes
  • Tableaux de bord
En savoir plus

Prospection

  • Fichiers de prospection sur mesure
  • 100 critères de segmentation
  • Adresses, mails et téléphones
En savoir plus

Enrichissement

  • Traitement de fichiers ou API
  • Siretisation et dédoublonnage
  • Information complète et indicateurs propriétaires
En savoir plus

Solution d'avis client

  • Collecte et certification
  • Tableaux de bord d'analyse
  • Diffusion web et réseaux sociaux
En savoir plus